MaMTH-DS platform workflow

In the latest issue of Nature Chemical Biology, the Stagljar lab used the mammalian membrane two-hybrid drug screening (MaMTH-DS), a technique that they previously pioneered, to identify new compounds that inhibit the activity of oncoproteins that cause breast cancer. In this case they found four compounds that inhibit the dimerization of the epidermal growth factor receptor (EGFR), which is commonly mutated in non-small-cell lung cancers that have become resistant to conventional chemotherapeutic reagents. One of the newly identified compounds would have not been identified by conventional assays.

This paper is featured in the latest issue of UofT News.